ERBB2 and breast carcinoma: Although it is reported that miR-223 is highly expressed in breast cancer and coordinates breast cancer progression 45, 46, most studies only focused on the expression pattern of miR-223, and found that the expression of miR-223 in luminal and HER2 subtypes of breast cancer is decreased, and high expression of miRNA-223 is an indicator of good prognosis in TNBC 47-49.